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Abstract
Objective: Multiple myeloma (MM) is characterized by malignant proliferation of plasmocytes and 
their precursors. T regulatory cells (Tregs) have a role in immunosuppression and control of autoim-
munity, and are currently an important topic in the study of immune response to tumor cells. The 
correlation between Tregs and autologous peripheral blood stem cell transplantation (APBSCT) in 
MM has not been studied. The aim of this study was to compare CD4+CD25+FOXP3+ Treg, CD200, 
and PD-1 levels in MM patients that did and did not undergo APBSCT. 
Materials and Methods: Peripheral blood samples were collected from 28 MM patients ranging in age 
from 41 to 78 years for analysis of CD4CD25+ FOXP3+ Tregs, PD-1 (CD279), and CD200. Peripheral 
blood mononuclear cells were isolated via density gradient centrifugation. Four-color flow cytometry 
was performed. Using a sequential gating strategy, Tregs were identified as CD4+CD25+FOXP3+ 
T-cells. Results were analyzed using the Mann Whitney U non-parametric test and a compare means 
test. p values <0.05 were considered statistically significant. 
Results: The study included 28 MM patients (10 female and 18 male). In all, 11 of the patients under-
went  APBSCT.  The  level  of  Tregs  identified  as  CD4+CD25+FOXP3+  T-cells  was  higher  in  the 
patients  that  underwent  APBSCT  (p=0.042).  CD200  and  PD-1  levels  did  not  significantly  differ 
between the 2 groups (p=0.711 and p=0.404, respectively). There weren’t any statistically significant 
differences in CD200, PD-1, or CD4+CD25+FOXP3+ T-cell levels between the patients that did and 
did not undergo APBSCT (p>0.05). 
Conclusion: Treg levels were higher in the patients that underwent APBSCT. Tregs are crucial for the 
induction and maintenance of peripheral tolerance to self-antigens. In addition, Tregs can suppress 
immune responses to tumor antigens; however, APBSCT and Treg levels were not correlated with 
CD200 or PD-1 expression. Relationship of Tregs with prognosis needs to be determined by studies 
that include larger cohorts. (Turk J Hematol 2011; 28: 107-14)
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Multiple Myeloma (MM) is characterized by malig-
nant  proliferation  of  plasmocytes  and  their  precur-
sors. It is an incurable clonal B-cell malignancy with 
terminally differentiated plasma cells [1,2]. The Durie-
Salmon  and  International  Staging  System  (ISS)  are 
used for MM staging [3,4]. Major advances in the treat-
ment  of  MM  include  immunomodulatory  drugs 
(lenalidomide  and  thalidomide)  and  proteosome 
inhibitors (bortezomib) [5]. The bone marrow (BM) 
microenvironment confers growth, survival, and drug 
resistance to MM cells via both direct cell contact and 
soluble factors. Thalidomide and immunomodulato-
ry  derivatives,  as  well  as  the  proteosome  inhibitor 
bortezomib, which can overcome clinical drug resis-
tance, act not only directly on MM cells, but also on 
the BM microenvironment to inhibit up-regulation of 
IL-6 and VEGF secretion triggered by the binding of 
MM cells to BM stem cells [6,7]. 
T regulatory cells (Tregs) play a role in immuno-
suppression and control of autoimmunity, and are 
currently an important topic in the study of immune 
response  to  tumor  cells.  Various  subsets  of  Tregs 
have been identified based on their expression of 
cell surface markers, production of cytokines, and 
mechanisms of action. Naturally occurring thymic-
derived CD4+CD25+ Tregs are a T-cell population 
with immunosuppressive properties that constitute 
5%-10%  of  peripheral  CD4+  T-cells  [8,9].  Recent 
studies have reported that the transcription factor 
forkhead box P3 (FOXP3) is an exclusive intracel-
lular marker for Tregs (10). In addition, FOXP3 is 
also  a  crucial  transcription  factor  in  the  develop-
ment  and  function  of  CD4+CD25+  Tregs.  FOXP3 
blocks the ability of Rel-family transcription factors 
NFAT and NFκB to induce their target genes, and as 
a consequence it acts as a transcriptional repressor 
of IL-2 and other cytokine genes (IL-4 and IFN-γ), 
thereby  programming  cells  not  to  exert  immune 
stimulatory functions. In brief, CD4+ Tregs are iden-
tified by their CD4+CD25+FOXP3+ expression pat-
tern [8-10]. Dysfunctional Tregs were observed in 
MM; as such, Tregs have become a novel target for 
research [11]. 
Özet
Amaç: Multipl miyelom (MM) plazmositlerin ve bunların öncü hücrelerinin habis proliferasyonu ile 
kendini gösteren bir hastalıktır. T düzenleyici (regülatör) hücreler (Treg) immünsüpresyonda ve oto-
immün sistemin denetiminde rol oynarlar. Ayrıca tümör hücrelerine karşı oluşan immün yanıttaki 
rolleri de güncel bir araştırma konusudur. Treg hücreleri MM’da otolog çevre kanı kök hücre nakli 
(APBSCT) ile ilişkili olarak daha önce araştırılmamıştır. Bu çalışmanın amacı, CD4+ CD25+ FoxP3+ 
Treg hücreleri ile, CD200 ve PD–1 ‘in APBSCT yapılmış ve yapılmamış MM hastalarındaki düzeyleri-
ni karşılaştırmaktır. 
Yöntem: Yaşları 41 ile 78 arasında 28 MM hastasından CD4+ CD25+ FoxP3+ Treg hücreleri ile, 
CD200 ve PD–1 (CD279) analizi için çevre kanı örnekleri alındı. Mononükleer hücreler dansite gra-
dient santrifüj yöntemi ile ayrıldı. Dört renkli akış sitometri ile uygulandı. Ardışık kapılamalar (gating) 
ile Treg hücreleri CD4+ CD25+ FoxP3+ T hücreleri olarak tanımlandı. Sonuçlar Mann Whitney U 
nonparametrik testi ve Compare Means testleri ile analiz edildi. P değerleri <0.05 olanlar istatistiksel 
açıdan anlamlı kabul edildi.
Bulgular: Bu çalışma 28 MM hastası (10 kadın, 18 erkek) içermektedir. Otolog çevresel kan kök hücre 
nakli 11 hastaya uygulanmıştır. CD4+ Treg hücreler CD4+ CD25+ FoxP3+ olarak saptanmış olup 
APBSCT alan hastalarda daha yüksek bulunmuştur (p=0.042). CD200 ve PD-1 iki grup arasında 
istatistiksel anlamlı bir sonuç göstermemiştir (sırasıyla; p=0.711 ve p=0.404). APBSCT yapılan ve 
yapılmayan gruplar arasında CD200, PD-1 ve CD4+CD25+FOXP3+ düzeyleri karşılaştırıldığında 
istatistiksel anlamlı bir sonuç bulunmamıştır (p>0.05). 
Sonuç: Bu çalışmada Treg hücreleri APBSCT yapılmış hastalarda daha yüksek düzeyde bulunmuştur. 
Treg hücrelerinin bireyin kendi hücrelerine karşı periferik toleransın indüklenmesinde ve korunmasın-
da çok önemli rolü olduğu bilinmektedir. Buna ek olarak, Treg hücreleri tümör antijenlerine karşı 
oluşturulacak immün yanıtı baskılayabilmektedir. Ne var ki, çalışmamızda APBSCT veya Treg hücre 
düzeyleri CD200 ve PD-1 ekspresyonları ile korelasyon göstermemiştir. Prognoz ile ilişkileri daha 
fazla sayıda olgu grupları içeren çalışmalarla aydınlatılabilir. (Turk J Hematol 2011; 28: 107-14)
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with  an  immunosuppressive  effect  on  T-cell-
mediated immunity and delivers immunoregulatory 
signals  following  engagement  of  CD200R.  It  is 
expressed by thymocytes, activated T-cells, B-cells, 
dendritic cells, endothelial cells, and neurons. Its up 
regulation is thought to be related to tumor cell eva-
sion  of  the  immune  system  [12,13].  CD200  is   
currently  considered  a  new  prognostic  factor  in   
MM [14]. Programmed death-1 (PD-1) and its ligands 
PD-L1 and PD-L2 deliver inhibitory signals that regu-
late  the  balance  between  T-cell  activation,  toler-
ance, and immunopathology. PD-1 is expressed on 
T-cells,  B-cells,  natural  killer  cells,  and  dendritic 
cells. PD-1 is not expressed on resting T-cells, but is 
inducibly expressed after activation [15]. PD-1 typi-
cally  has  a  greater  effect  on  cytokine  production 
than on cellular proliferation, with significant effects 
on  IFN-γ,  TNF-α,  and  IL-2  production  [16].  PD-1 
expression is upregulated on tumor-infiltrating lym-
phocytes,  which  may  also  contribute  to  tumor 
immunosuppression, and stimulates T-cell apopto-
sis.  Its  inhibition  is  related  to  tumor  progression. 
PD-L1  negatively  regulates  CD4+CD25+FOXP3+ 
Tregs by limiting STAT-5 phosphorylation [17]. 
T-cells non-responsive to tumor cells have been 
reported in MM (1,2). As such, immunosuppressive 
CD4+CD25+FOXP3+  Tregs,  PD-1,  and  CD200-a 
novel prognostic factor in MM-were selected as the 
subjects of the present study. CD4+CD25+FOXP3+ 
Tregs  have  a  high  level  of  expression  in  patients   
that undergo allogeneic bone marrow transplanta-
tion [18]. CD200 is also considered a novel prognos-
tic  factor  in  MM,  with  high  expression  [14]. 
Additionally, PD-1 is related to tumor immunosup-
pression, but PD-1 levels in MM patients that under-
went autologous peripheral blood stem cell trans-
plantation (APBSCT) haven’t been reported. Based 
on  this  knowledge,  our  hypothesis  was  that 
CD4+CD25+  FOXP3+  Tregs,  CD200,  and  PD-1 
would  have  higher  levels  of  expression  in  MM 
patients that underwent APBSCT. As such, the aim 
of  the  present  study  was  to  compare  the  leve 
CD4CD25+ FOXP3+ Treg, CD200, and PD-1 levels in 
MM patients that did and did not undergo APBSCT.
Materials and Methods
This prospective study’s protocol was approved 
by the Dokuz Eylul University Medical Faculty Ethics 
Committee. Blood samples were not collected from 
a  biobank.  Fresh  blood  samples  were  collected 
from volunteer MM patients that were diagnosed, 
treated, and followed-up at our hematology depart-
ment.  MM  patients  that  did  and  did  not  undergo 
APBSCT were included in the study. For MM patients 
that did not undergo APBSCT allogeneic stem cell 
transplantation  was  an  exclusionary  criterion. 
Patients that did not volunteer to participate were 
excluded from the study. 
 
Patient characteristics
This study included 28 MM patients aged 41-78 
years. Documentation about the aim of the study 
and  procedures  for  collecting  blood  samples  not 
associated  with  MM  treatment  were  prepared  in 
advance. Written informed consent was obtained 
from each volunteer participant. In all, 10 patients 
were female and 18 were male. All patients received 
first-line  therapies  and  11  patients  underwent 
APBSCT.  Blood  was  collected  40-110  d  following 
transplantation. All of the APBSCT patients received 
the  same  mobilization  protocol,  which  included 
high-dose  cyclophosphamide.  Patient  clinical 
parameters  and  therapies  were  recorded  at  the 
time of sample collection and analysis. Patients that 
did not undergo APBSCT were treated with a com-
bination of vincristine, adriamycin, and dexametha-
sone (VAD) (n=3) or cyclophosphamide and dexa-
methasone combination (CYP+DEX) (n=8). Only 2 
cases were treated with a melphalan prednisolone 
combination (MP). Sample collection and analysis 
were  performed  on  the  same  day  so  that  the 
parameters and therapies at the time of sample col-
lection and analysis would not differ. Frozen sam-
ples were not used in the study. 
Sample collection and preparation
CD4CD25+Foxp3+  Tregs  have  a  high  level  of 
expression in solid tumors, but as MM is a hemato-
logical malignancy sufficient quantities for flow cyto-
metric analysis were obtained from peripheral blood 
samples  [19-21].  We  did  not  collect  samples  from 
bone marrow because,  it would has  been a corrosive 
procedure  for  the  patients  to  get  enough  sample. 
Peripheral blood samples were collected into sterile 
EDTA containers for analysis of CD4CD25+ FOXP3+ 
Tregs, PD-1 (CD279), and CD200. Samples were dilut-
ed with phosphate buffer saline solution. Peripheral 
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density  gradient  centrifugation  in  Biocoll  separating 
solution (density: 1.077 g mL-1, Biochrom) and under-
went immediate analysis by flow cytometry. 
 
Flow cytometry
Four-color flow cytometry was performed on an 
Epics  XL  (Beckman  Coulter)  and  analyzed  with 
Expo 32 ADIC XL 4 Color software. Directly conju-
gated monoclonal antibodies (mAbs) against CD4-
FITC,  CD25-pyhcoerythryrin  (PE)  (eBioscience), 
and  PD-1-  FITC/CD200-PE  (BD  Biosciences),  and 
appropriate IgG isotype controls were used to stain 
mononuclear  cells.  Isolated  PBMCs  underwent 
immediate  staining  procedures.  Frozen  or  ripe 
samples were not used for flow cytometry staining 
or  analysis.  Fixation  and  permeabilization  proce-
dures were used for intracellular indirect staining. 
Co-staining of intracellular FOXP3 was performed 
via application of the PE-Cy5 conjugated anti-FOXP3 
clone  PCH101  (eBioscience).  Staining  protocols 
were  performed  according  to  the  manufacturers’ 
instructions.  During  all  staining  procedures  non-
specific conjugation was blocked via use of normal 
rat serum. Using a sequential gating strategy Tregs 
were  identified  as  CD4+CD25+FOXP3+  T-cells. 
CD200 and PD-1 levels were also determined using 
a sequential gating strategy.
Statistical analysis
Results  were  analyzed  using  the  Mann-Whitney 
non-parametric U test, Pearson’s correlation analysis, 
and the Kaplan Meier survival analysis test. P values 
<0.05  were  considered  statistically  significant. 
Survival was compared according Treg high and low 
levels. Mean values were taken as the cut off for high 
ands low Treg levels. Kaplan Meier survival curves 
were established regardless of patient transplanta-
tion status for comparison of Treg high and low popu-
lations.  Both  groups  included  transplant  or  non-
transplant patients. The study did not include a suffi-
cient number of patients for forming subgroups.
Results
This study included 28 MM patients (10 female 
and 18 male). In all, 11 of the patients underwent 
APBSCT. The clinical and histological features of the 
patients that did [APBSCT (+)] and did not [APBSCT 
(-)] undergo APBSCT are shown in Tables 1 and 2, 
respectively. 
Flow cytometry results 
CD4+CD25+FOXP3+ Treg, CD200+, and PD-1+ 
T-cell levels were determined using sequential and 
appropriate gating strategies. CD4+CD25+FOXP3+ 
Treg levels ranged between 0% and 11% in all the 
cases, between 0.07% and 9% in the APBSCT (+) 
cases, and between 0% and 11% in the APBSCT (-) 
cases. CD200+ cell levels ranged between 0.1% and 
7.08% in all the cases, between 0.1% and 6.72% in 
the  APBSCT  (+)  cases,  and  between  0.1%  and 
7.08% in the APBSCT (-) cases. The level of cells 
expressing PD-1 ranged between 0% and 50.66% in 
Table 1. Clinical and histological features of the APBSCT (+) 
cases (n=11)
Gender
  Female   5  45.5%
  Male   6  54.5%
  Kappa (K)  5  45.5%
Light Chain-Type  Lamda (L)  5  45.5%
  NA  1  4.0%
  IgG  7  63.6%
Ig Heavy Chain-Type  IgA  2  18.2%
  NA  2  18.2%
  Stage 1  2  18.2%
ISS  Stage 2  5  45.5%
  Stage 3  2  18.2%
  NA  1  9.1%
  IA  1  9.1%
  IIA  3  27.3%
Durie-Salmon Stage  IIIA  3  27.3%
  IIIB  3  27.3%
  NA  2  9.1%
  Diffuse  5  45.5%
Bone Marrow Biopsy  Nodulary  5  45.5%
  Diffuse and Nodulary  1  9.1%
  VAD  6  54.5%
Therapy  CYP + DEX  4  36.4%
  NA  1  9.1%
  CR  1  9.1%
  PR  6  54.5%
Therapy Response  SD  2  18.2%
  Refractory  1  9.1%
  NA  1  9.1%
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(+)  cases,  and  between  0%  and  50.66%  in  the 
APBSCT (-) cases. Flow cytometry results for CD4+ 
T-cells, CD4+CD25+FOXP3+ Tregs, PD-1 (+), and 
CD200 (+) T-cells are shown in Table 3.
Statistical results 
The level of CD4+ Tregs identified according to 
CD4+CD25+FOXP3+ was higher in the APBSCT (+) 
patients (p=0.042) (Figure 1). CD200 and PD-1 levels 
did not significantly differ between the APBSCT (+) 
and  APBSCT  (-)  patients  (p=0.711  and  p=0.404, 
respectively)  (Figures  2  and  3).  The  CD4+  T-cell 
population  did  not  significantly  differ  between  the 
APBSCT  (+)  and  APBSCT  (-)  patients  (p=0.353). 
CD4+  T-cell  and  CD4+CD25+FOXP3+  Treg  levels 
were  not  correlated  with  transplantation  status 
(p=0.137). CD4+ T-cells were correlated with CD200- 
and PD-1-expressing T-cells, according to transplan-
tation  status  (p=0.011  and  p=0.021,  respectively). 
Based on correlation analysis performed separately 
Table 2. Clinical and histological features of the APBSCT (-) 
cases (n=17)
Gender
  Female  5  29.4%
  Male  12  70.6%
  Kappa (K)  14  82.4%
Light Chain-Type  Lamda (L)  2  11.8%
  NA  1  5.8%
  IgG  12  70.6%
Ig Heavy Chain-Type  IgA  3  17.6%
  NA  2  12.8%
  Stage 1  7  41.2%
  Stage 2  3  17.6%
ISS
  Stage 3.  3  17.6%
  NA  4  23.6%
  IA  7  41.2%
  IIA  5  29.4%
Durie-Salmon Stage  IIB  2  11.8%
  IIIA  1  5.9%
  NA  2  12.8%
  Diffuse  9  52.9%
  Nodulary  3  17.6%
Bone Marrow Biopsy
  Diffuse and Nodulary  3  17.6%
  NA  2  12.8%
  VAD  3  17.6%
  CYP + DEX  8  47.1%
Therapy  MP  2  11.8%
  NA  4  29.5%
  CR  3  17.6%
  PR  7  41.2%
Therapy Response  SD  1  5.9%
  Refractory  2  11.8%
  NA  4  23.6%
Figure 1. Comparison of CD4+CD25+FOXP3+ Treg levels between 
APBSCT (+) (n=11) and APBSCT (-) (n=17) patients’ peripheral 
blood samples (n=28). The percentage of Tregs in the peripheral 
blood of APBSCT (+) patients was significantly higher than that in 
the peripheral blood of APBSCT (-) patients
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T-cell levels were positively correlated with CD200- 
and PD-1-expressing T-cells in the APBSCT (-) patients 
(p=0.013 and p=0.035, respectively). There wasn’t a 
statistically significant difference in CD200, PD-1, or 
CD4+CD25+FOXP3+  levels  between  the  APBSCT 
(+) and APBSCT (-) patients (p>0.05). According to 
Pearson’s correlation analysis, CD4+CD25+FOXP3+ 
Tregs  were  not  correlated  with  CD200-  or  PD-1-
expressing T-cells in the APBSCT (-) patients (p>0.05); 
however,  a  significant  correlation  was  observed 
between  CD200-  and  PD-1-expressing  T-cells 
(p=0.005).  Kaplan  Meier  survival  analysis  showed 
that MM patients with high Treg concentrations had 
longer event-free survival than MM patients with low 
Treg concentrations (Figure 4). 
 
Discussion
In the present study Treg levels were higher in 
the APBSCT (+) patients. Tregs are crucial for the 
induction and maintenance of peripheral tolerance 
Table  3.  Flow  cytometry  results  for  CD4+  T-cells,  CD4+ 
CD25+FOXP3+ Tregs, and PD-1+ and CD200+ T-cells 
APBSCT  Patient   CD4 (+)  CD4 (+)  CD200   PD-1
  no.  T-cells   CD25 (+)   (+)  (+)
      FOXP3 (+) 
  1  21.1%  0.5%  4.2%  2.2%
  2  10.4%  2.8%  1.9%  1.0%
  3  6.7%  9.0%  0.9%  0.4%
  4  6.3%  6.6%  0.8%  0.6%
+  5  7.4%  1.4%  1.1%  0.2%
  6  12.7%  4.9%  0.1%  0.0%
  7  19.1%  1.4%  6.7%  12.1%
  8  17.24%  1.8%  1.54%  3.83%
  9  7.34%  1.47%  6.72%  4.84%
  10  8.23%  0.07%  0.79%  50.66%
  11  8.78%  3.53%  6.62%  4.63%
  12  5.6%  11.0%  0.1%  0.2%
  13  4.9%  1.1%  1.2%  1.4%
  14  3.8%  0.0%  0.5%  3.0%
  15  4.7%  1.4%  0.5%  0.9%
  16  8.3%  1.9%  4.6%  1.0%
  17  11.0%  0.5%  0.9%  0.1%
  18  17.8%  3.9%  1.3%  1.6%
-  19  68.03%  0.73%  3.2%  44.42%
  20  12.0%  2.33%  0.98%  5.35%
  21  11.79%  0.51%  0.52%  4.61%
  22  21.47%  0.19%  2.57%  16.77%
  23  17.41%  1.69%  2.11%  4.57%
  24  27.94%  0.71%  2.88%  26.79%
  25  37.98%  0.04%  1.28%  2.5%
  26  11.48  0.08%  7.08%  53.02
  27  28.2%  0.08%  5.05%  2.64%
  28  14.24%  0.05%  1.01%  6.88%
Figure 4. Event-free survival analysis of all the MM patients. MM pa-
tients with higer Treg concentrations had longer survival than MM 
patients with low Treg concentrations
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immune responses to tumor antigens; however, in 
the present study APBSCT and Treg levels were not 
correlated  with  CD200  or  PD-1  expression. 
Relationship of T regs with prognosis needs to be 
determined by studies that include larger cohorts.
The  CD4+CD25+FOXP3+  trio  is  used  in  the 
present study because according to the literature it 
is the most widely used method. Accordingly, flow 
cytometry was used in the present study because of 
its ability to detect levels of this combination.
Atanackovic et al. reported that Treg reconstitu-
tion  resulted  in  accumulation  of  donor-derived 
CD4+CD25+FOXP3+ cells in the BM of MM patients 
following APBSCT. They suggested that Tregs might 
contribute to the prevention of graft versus host dis-
ease  via  their  immunosuppressive  effect  [18]. 
Similarly, high Treg populations were noted in the 
APBSCT  (+)  patients  post  surgery  in  the  present 
study, suggesting that Tregs may play a role in stimu-
lation of the immune system after  APBSCT. 
CD200 is thought to induce Tregs that inhibit the 
immune  response  of  tumor-specific  effector  T-cells 
[22]. In contrast, Treg levels in the present study were 
not  correlated  with  CD200-expressing  T-cells  in  the 
present study. In future studies this incongruity could 
be solved by studying BM, which better reflects the 
tumor microenvironment. Moreaux et al. reported that 
MM cases without CD200 expression have significantly 
longer  event  free-survival  than  CD200-expressing 
cases  [14];  however,  no  such  relationship  was 
observed in the present study. Moreaux et al.’s study 
included 112 cases and MM cells in BM were investi-
gated, whereas the present study included 28 cases 
and PBMCs were investigated, which might account 
for the different results obtained in each study. 
Benson et al. reported that monoclonal antibody 
anti-PD-1 could be a novel immunotherapy for MM 
because its inhibition upregulates T-cell activation 
and immune response [23]. Accordingly, the rela-
tionship between PD-1 and novel prognostic factor 
CD200 should be considered. A significant correla-
tion  was  observed  between  CD200-  and  PD-1-
expressing T-cells in the present study, but the role 
of  this  correlation  on  immune  response  in  MM 
should be analyzed in future studies.
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